Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up. The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
93
The product is not used directly on the subject, but on a blood sample taken from the participant.
CMC Ambroise Paré Hartmann
Neuilly-sur-Seine, France
RECRUITINGEvolution of the kinetics of CTC during treatment
Evolution of the number of CTC isolated by ScreenCell technology thanks to a blood draw during the therapeutic management of metastatic and infiltrative non-metastatic breast cancer patients. Average number of CTCs measured during the study (D0, W6, W12, W24, W36)
Time frame: From enrollement to the end of follow up at 9 months
Molecular characterisation of CTC
Analysis of the expression of specific antigens and the presence of informative mutations on CTCs isolated by ScreenCell technology thanks to a blood draw during the therapeutic management of metastatic and infiltrative non-metastatic breast cancer patients during the study (D0, W6, W12, W24, W36)
Time frame: From enrollement to the end of follow up at 9 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.